Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0EM4S
|
||||
| Former ID |
DNCL001608
|
||||
| Drug Name |
JNJ-39439335
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Musculoskeletal pain [ICD9: 338,780; ICD10:R52, G89] | Phase 1 | [1] | ||
| Company |
Johnson & Johnson Pharmaceutical Research & Development
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C25H21F3N2O
|
||||
| Canonical SMILES |
CC(C)(C1=CC=CC=C1C2=CC3=C(C=C2)N=C(N3)C=CC4=CC=C(C=C4)C<br />(F)(F)F)O
|
||||
| InChI |
1S/C25H21F3N2O/c1-24(2,31)20-6-4-3-5-19(20)17-10-13-21-22(15-17)30-23(29-21)14-9-16-7-11-18(12-8-16)25(26,27)28/h3-15,31H,1-2H3,(H,29,30)/b14-9+
|
||||
| InChIKey |
ORDHXXHTBUZRCN-NTEUORMPSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Vanilloid receptor 1 | Target Info | Antagonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | ||||
| Trk receptor signaling mediated by PI3K and PLC-gamma | |||||
| Reactome | TRP channels | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01631487) A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants. U.S. National Institutes of Health. | ||||
| REF 2 | Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep). J Med Chem. 2015 May 14;58(9):3859-74. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.